PARIS, France ( TheStreet) -- Sanofi-Aventis ( SNY - Get Report) announced Wednesday that an experimental drug for limb ischemia failed a late-stage study.

The Sanofi drug NV1FGF failed to demonstrate superiority over a placebo in the prevention of amputation or death in patients with critical limb ischemia who were not eligible for surgery.

Limb ischemia is a condition in which the large arteries of the legs or arms become blocked. Sanofi developed NV1FGF to help grow new blood vessels to improve blood circulation.Sanofi, which is seeking to acquire the U.S. biotech firm Genzyme ( GENZ), was developing NV1FGF in a partnership with Vical ( VICL - Get Report).

Full details from the failed study will be presented at the American Heart Association meeting in November, Sanofi said.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.